BMS Slashes Sotyktu Price by Over 80% Amid Rising Competition from JNJ-2113

Sep 28, 2025 18:31 CST Updated 18:31

Johnson & Johnson

Medical Device R&D and Manufacturer

China's innovative drugs enter the "three era," with new forms such as tri-specific antibodies, tri-specific TCE, and tri-specific ADC emerging one after another.
At present, European and American pharmaceutical companies and VC firms are actively seeking tri-specific antibody products, especiallyThree AntibioticsTCE(such as: CD38xCD3xBCMA, CD38xCD3xCD28, CD38xCD3xGPRC5D).
Interested companies are invited to contact the PharmTimes BD team immediately.（BD@drugtimes.cn）！
Main Body: 1000Word 1 Image
Estimated reading time: 3Minute

JNJ-2113 is about to be launched.Sotyktu price drops by over 80%.

On September 25, 2025, BMS announced that it wouldEliquis (Apixaban) and Sotyktu (Deucravacitinib) have significantly reduced their prices.Eliquis Self-Pay Price Reduced by Over 40%,SotyktuSelf-paid price reduced by more than 80%

Image Source: BMS Official Website

The news about the price reduction of Eliquis was announced earlier this month. On September 8th,BMS and Pfizer Jointly Launch "Eliquis 360 Support" Direct Sales Program, Providing Assistance for PurchasesEliquis self-paying patients receive a 40% discount.

And this price reduction of Sotyktu will be implemented through BMS's newly launchedSupplied by the Patient Direct Connect Platform (BMS Patient Connect),The start time is January 2026.

Sotyktu is the world's first TYK2 inhibitor, approved by the FDA in September 2022 for the treatment of adults with moderate to severe plaque psoriasis. Moreover, the FDA did not add a black box warning to Sotyktu's label, making it the first JAK inhibitor without a black box warning.

However, such a halo did not bring ideal commercial returns. In 2024, the annual sales of Sotyktu were $246 million, lower than market expectations,Far from BMS's predicted "peak sales of $4 billion."

BMS explained that the competition in the psoriasis market is intense, and the difficulty of market access is greater than expected, with influencing factors including but not limited to doctors' prescription rights and channel advantages.

This time, BMS announced the launch of "BMS Patient Connect"Perhaps this consideration also exists,Capture the self-paying patients through direct sales to seize the market share.

According to Business Wire, the current list price for Sotyktu is$6,828/month,And self-paying patients who purchase through the BMS Patient Connect platform only need to pay$950/month,The price reduction is as high as 86%.

In addition to opening up the market, Johnson & Johnson's oralPsoriasis DrugsThe NDA of JNJ-2113 is also deeply stimulating BMS's nerves.

JNJ-2113 is the world's first oral antagonist peptide targeting IL-23 to enter clinical stage, developed by Johnson & Johnson and Protagonist.Co-developed, designed for once-daily oral administration.

In July this year,Johnson & Johnson announcedTo the United StatesFDASubmitNDA, Seeking ApprovalJNJ-2113，Used for treatment12Years and above with moderate to severe plaque psoriasis (PsO) Adult and pediatric patients.

References:World's First! Johnson & Johnson's IL-23 Oral Peptide Submitted for Market Approval

If it were just a simple competitor product launch, it wouldn't make BMS nervous. The fear is,The competition is too strong. On September 17 this year, Johnson & Johnson announced two Phase IIIICONIC-ADVANCE 1And the latest data from ICONIC-ADVANCE 2 show that,JNJ-2113 Outperforms in Both PASI90 and PASI100Sotyktu。

HerePASI90, which isThe PASI score decreased by 90% or more after the treatment compared to before the treatment.In other words, the majority of skin lesions have subsided after treatment, indicating a significant improvement in the condition. Therefore, a reduction of the PASI score to 100% is generally considered as "clinical cure."

In this way, BMS doesn't have much time left, and reducing the price is undoubtedly the most aggressive and direct response.

References:

1.https://news.bms.com/news/details/2025/Bristol-Myers-Squibb-Builds-on-Eliquis-apixaban-Direct-to-Patient-Program-Announces-New-BMS-Patient-Connect-Platform-Offering-Sotyktu-deucravacitinib/default.aspx

2.https://news.bms.com/news/details/2025/Bristol-Myers-Squibb-Builds-on-Eliquis-apixaban-Direct-to-Patient-Program-Announces-New-BMS-Patient-Connect-Platform-Offering-Sotyktu-deucravacitinib/default.aspx

3.World's First! Johnson & Johnson's IL-23 Oral Polypeptide Submitted for Market Approval

4.2113 Is Coming, TYK2 Prices Drop First (Medicine Monster Stand Still)

5. Other Public Information

Image Source: Jimo AI

Global Top Investment Firms Rush to Enter China! RA Capital Visits Again to Discuss Building an International Early-Stage Innovation R&D Platform with the GCP Center at Yizhong Langfang Campus

2025-09-27

NIH Establishes the First National Organoid Research and Development Center in the U.S.! A "Savior" for Lab Animals?

2025-09-27

Why Did Luye Pharma's Stock Price Surge 16% After Eli Lilly Terminated Clinical Trials?

2025-09-26

Copyright Statement/Disclaimer
This article is an original piece.
This article is for informational exchange only and does not provide any commercial, medical, or investment advice.
The images, videos, fonts, music and other materials in the article are either authorized genuine works purchased by PharmaTimes, or from the WeChat public image library, or taken from the company's official website/network. Some materials are used under the CC0 protocol. All copyrights belong to the respective owners, and PharmaTimes makes every effort to acknowledge the sources.
If you have any questions, please contact us.
Sincerely grateful!
DrugTimes Official Website: www.drugtimes.cn
Contact Information:
Phone: 13651980212
WeChat: 27674131
Email: contact@drugtimes.cn
ClickView more highlights!